PL2536742T3 - Leczenie zaburzeń żołądkowo-jelitowych - Google Patents

Leczenie zaburzeń żołądkowo-jelitowych

Info

Publication number
PL2536742T3
PL2536742T3 PL11706694T PL11706694T PL2536742T3 PL 2536742 T3 PL2536742 T3 PL 2536742T3 PL 11706694 T PL11706694 T PL 11706694T PL 11706694 T PL11706694 T PL 11706694T PL 2536742 T3 PL2536742 T3 PL 2536742T3
Authority
PL
Poland
Prior art keywords
treatments
gastrointestinal disorders
gastrointestinal
disorders
Prior art date
Application number
PL11706694T
Other languages
English (en)
Inventor
Angelika Fretzen
Hong Zhao
Marco Kessler
Original Assignee
Ironwood Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43875305&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2536742(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ironwood Pharmaceuticals, Inc. filed Critical Ironwood Pharmaceuticals, Inc.
Publication of PL2536742T3 publication Critical patent/PL2536742T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL11706694T 2010-02-17 2011-02-17 Leczenie zaburzeń żołądkowo-jelitowych PL2536742T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30546510P 2010-02-17 2010-02-17
EP11706694.4A EP2536742B1 (en) 2010-02-17 2011-02-17 Treatments for gastrointestinal disorders

Publications (1)

Publication Number Publication Date
PL2536742T3 true PL2536742T3 (pl) 2017-11-30

Family

ID=43875305

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11706694T PL2536742T3 (pl) 2010-02-17 2011-02-17 Leczenie zaburzeń żołądkowo-jelitowych

Country Status (13)

Country Link
US (6) US8933030B2 (pl)
EP (1) EP2536742B1 (pl)
CN (1) CN102869677B (pl)
AU (3) AU2011218009B2 (pl)
CA (1) CA2790213A1 (pl)
DK (1) DK2536742T3 (pl)
EA (1) EA201290799A1 (pl)
ES (1) ES2638589T3 (pl)
MX (2) MX340234B (pl)
PL (1) PL2536742T3 (pl)
TR (1) TR201711271T4 (pl)
UA (1) UA108636C2 (pl)
WO (1) WO2011103311A2 (pl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012034068A1 (en) * 2010-09-11 2012-03-15 Ironwood Pharmaceuticals, Inc. Treatment of constipation-predominant irritable bowel syndrome
HUE032237T2 (en) 2011-08-17 2017-09-28 Ironwood Pharmaceuticals Inc Treatments for gastrointestinal disorders
CN102875655B (zh) * 2012-09-29 2014-12-17 深圳翰宇药业股份有限公司 一种合成利那洛肽的方法
CN104231051B (zh) * 2013-06-06 2020-06-26 深圳翰宇药业股份有限公司 一种利那洛肽的制备方法
KR20160042039A (ko) 2013-08-09 2016-04-18 알데릭스, 인코포레이티드 인산염 수송을 억제하기 위한 화합물 및 방법
UA119335C2 (uk) * 2013-12-11 2019-06-10 Айронвуд Фармасьютикалз, Інк. Композиції лінаклотиду з затриманим вивільненням
WO2015166468A1 (en) * 2014-05-02 2015-11-05 Sinoveda Canada, Inc. Formulas comprising highly soluble elements and vitamin d for the prevention and treatment of bowel conditions during calcium supplementation
HUE061954T2 (hu) * 2015-05-01 2023-09-28 Ironwood Pharmaceuticals Inc Vastagbél tisztítására és gyomor-bélrendszeri rendellenességek kezelésére szolgáló készítmények
EP3558337A1 (en) 2016-12-21 2019-10-30 Ironwood Pharmaceuticals, Inc. Methods of treating irritable bowel syndrome with modified or delayed release formulations of linaclotide
US10695402B2 (en) 2017-03-16 2020-06-30 University Of Rochester Erythropoietin for gastrointestinal dysfunction
CN106831950A (zh) * 2017-03-18 2017-06-13 南京工业大学 一种制备利那洛肽的方法
IT201700054380A1 (it) * 2017-05-19 2018-11-19 Aboca Spa Societa Agricola Composizioni contenenti sistemi di rilascio di anidride carbonica ottenuti da succhi vegetali
WO2020237096A1 (en) 2019-05-21 2020-11-26 Ardelyx, Inc. Combination for lowering serum phosphate in a patient
WO2025226772A1 (en) * 2024-04-23 2025-10-30 Cindome Pharma, Inc. Methods for treating gastroesophagael symptoms in cystic fibrosis patients

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH658973A5 (fr) 1983-12-29 1986-12-31 Nestle Sa Produit aromatisant.
JPS6197229A (ja) 1984-10-18 1986-05-15 Chugai Pharmaceut Co Ltd 安定なエリトロポエチン製剤
DE3729863A1 (de) 1987-09-05 1989-03-16 Boehringer Mannheim Gmbh Stabilisierte erythropoietin-lyophilisate
JPS649938A (en) 1987-06-30 1989-01-13 Agency Ind Science Techn Oral ingestive composition
JPH03505334A (ja) 1989-04-11 1991-11-21 イミユノバイオロジー・リサーチ・インスチチユート・インコーポレーテツド 凍結乾燥されたペプチド製剤
IT1240314B (it) 1989-09-28 1993-12-07 Immunobiology Research Institutes, Inc. Formulazioni acquose stabilizzate di piccoli peptidi.
US5221495A (en) 1990-04-13 1993-06-22 Colgate-Palmolive Company Enzyme stabilizing composition and stabilized enzyme containing built detergent compositions
US5451410A (en) 1993-04-22 1995-09-19 Emisphere Technologies, Inc. Modified amino acids for encapsulating active agents
US6284727B1 (en) 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
US5681811A (en) 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
US5654278A (en) 1994-10-13 1997-08-05 Novo Nordisk A/S Composition and method comprising growth hormone and leucine
US5593696A (en) 1994-11-21 1997-01-14 Mcneil-Ppc, Inc. Stabilized composition of famotidine and sucralfate for treatment of gastrointestinal disorders
CH689139A5 (de) 1995-04-03 1998-10-30 Cerbios Pharma Sa Verfahren zur Herstellung einer liposomalen, in Wasser dispergierbaren, oral zu verabreichenden, festen, trockenen therapeutischen Formulierung.
US5904935A (en) 1995-06-07 1999-05-18 Alza Corporation Peptide/protein suspending formulations
ZA965368B (en) 1995-07-14 1997-01-14 Novo Nordisk As A pharmaceutical formulation
US5912014A (en) 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
CZ433898A3 (cs) 1996-07-03 1999-04-14 Alza Corporation Nevodné protické peptidové formulace
US5916582A (en) 1996-07-03 1999-06-29 Alza Corporation Aqueous formulations of peptides
US5932547A (en) 1996-07-03 1999-08-03 Alza Corporation Non-aqueous polar aprotic peptide formulations
US6541606B2 (en) 1997-12-31 2003-04-01 Altus Biologics Inc. Stabilized protein crystals formulations containing them and methods of making them
US6087478A (en) 1998-01-23 2000-07-11 The Rockefeller University Crystal of the N-terminal domain of a STAT protein and methods of use thereof
EP1098636A1 (en) 1998-07-23 2001-05-16 Novo Nordisk A/S A wet granulation method for preparing a stable pharmaceutical formulation
ID29085A (id) 1998-11-27 2001-07-26 Kanji Takada Suatu formulasi oral untuk penghantaran obat gastrointestinal
WO2001052937A1 (en) 2000-01-24 2001-07-26 Medtronic Minimed, Inc. Mixed buffer system for stabilizing polypeptide formulations
IL153688A0 (en) 2000-06-28 2003-07-06 Teva Pharma Carvedilol
FR2811884B1 (fr) 2000-07-21 2003-01-31 Oreal Utilisation en cosmetique de betainates d'amidon et composition les comprenant associes a au moins un agent benefique pour les matieres keratiniques
US6613308B2 (en) 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
WO2002026248A1 (en) 2000-09-29 2002-04-04 Cognetix, Inc. Stable peptide formulations
EP1351704B1 (en) 2000-12-21 2007-03-07 Nektar Therapeutics Storage stable powder compositions of interleukin-4 receptor
AU2002235520A1 (en) 2001-02-02 2002-08-19 Pharmacia Corporation Uroguanylin and cyclooxygenase-2 inhibitor combinations for inhibition of intestinal cancer
GB0104371D0 (en) 2001-02-22 2001-04-11 Clariant Int Ltd Color improving stabilizing compositions comprising leucine
US6573237B2 (en) 2001-03-16 2003-06-03 Eli Lilly And Company Protein formulations
JP4206272B2 (ja) 2001-03-29 2009-01-07 サイナージィ ファーマスーティカルズ、インコーポレイテッド 組織炎症及び発癌を治療するためのグアニル酸シクラーゼ受容体アゴニスト
WO2003014304A2 (en) 2001-08-09 2003-02-20 Doctor's Signature Sales And Marketing International Corp. [(Dba)] Life Force International Protonic formulation
US20030104996A1 (en) 2001-08-30 2003-06-05 Tiansheng Li L-methionine as a stabilizer for NESP/EPO in HSA-free formulations
US20040161776A1 (en) 2001-10-23 2004-08-19 Maddon Paul J. PSMA formulations and uses thereof
EP1458407A1 (en) 2001-12-21 2004-09-22 Novo Nordisk A/S Liquid composition of modified factor vii polypeptides
JP2003201256A (ja) 2001-12-28 2003-07-18 Hisamitsu Pharmaceut Co Inc 大腸送達性経口医薬製剤、大腸癌治療用経口医薬製剤および大腸炎治療用経口医薬製剤
DE10261126A1 (de) 2002-08-13 2004-03-04 Aventis Behring Gmbh Lagerungsstabile, flüssige Fibrinogen-Formulierung
CN1726012A (zh) 2002-12-11 2006-01-25 辉瑞产品公司 活性物质在高脂肪环境中的控制释放
US7371727B2 (en) 2003-01-28 2008-05-13 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
ATE477268T1 (de) 2003-01-28 2010-08-15 Ironwood Pharmaceuticals Inc Zusammensetzungen zur behandlung von magen-darm- störungen
US7304036B2 (en) 2003-01-28 2007-12-04 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7772188B2 (en) * 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
ATE390142T1 (de) 2003-05-14 2008-04-15 Indus Biotech Pvt Ltd Synergistische zusammensetzung zur behandlung von diabetes mellitus
ATE553747T1 (de) 2003-06-10 2012-05-15 Lg Life Sciences Ltd Stabile wässrige lösung von human-erythropoietin, die kein serumalbumin enthält
US7494979B2 (en) 2003-06-13 2009-02-24 Ironwood Pharmaceuticals, Inc. Method for treating congestive heart failure and other disorders
US20070010450A1 (en) 2003-06-13 2007-01-11 Microbia, Inc., A Massachusetts Corporation Methods and compositions for the treatment of gastrointestinal disorders
KR100560697B1 (ko) 2003-08-06 2006-03-16 씨제이 주식회사 알부민을 함유하지 않는 에리스로포이에틴 제제
DE202004020676U1 (de) 2004-03-10 2005-11-10 Bioceuticals Arzneimittel Ag Erythropoietin-Flüssigformulierung
CN101094651B (zh) 2004-12-30 2011-03-09 多贝尔有限公司 含有胶原凝集素家族蛋白质或者其变体的喷雾干燥的组合物和其制备方法
WO2007022531A2 (en) 2005-08-19 2007-02-22 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
WO2007044375A2 (en) 2005-10-06 2007-04-19 Nastech Pharmaceutical Company Inc. Pth formulations and methods of use
WO2007095716A1 (en) 2006-02-23 2007-08-30 Iomedix Sleep International Srl Compositions and methods for the induction and maintenance of quality sleep
EP1996218A4 (en) 2006-02-24 2012-07-11 Ironwood Pharmaceuticals Inc METHODS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS
ITMI20060629A1 (it) 2006-03-31 2007-10-01 Daniele Giovannone Composizioni solide orali a base di s-adenosilmetionina e processo per il loro ottenimento
AU2007272272B2 (en) 2006-07-10 2012-04-12 Pba3 Biomed Gmbh Antimicrobial peptides
CA2670821C (en) 2006-08-09 2012-05-15 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
CA2661521C (en) 2006-08-31 2016-04-12 Novartis Ag Pharmaceutical compositions comprising hgh for oral delivery
EP2114379A2 (en) 2006-12-20 2009-11-11 Bayer HealthCare LLC Factor vii and viia compositions
EP2650303A1 (en) 2007-02-26 2013-10-16 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of heart failure and other disorders
MX2009013293A (es) * 2007-06-04 2010-02-15 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos.
US20120213846A1 (en) 2008-08-15 2012-08-23 Forest Laboratories Holdings Limited Stable Solid Formulation of a GC-C Receptor Agonist Polypeptide Suitable for Oral Administration
US20120009225A1 (en) 2008-09-04 2012-01-12 Ironwood Pharmaceuticals, Inc. Stable Solid Formulation of Therapeutic Polypeptides Suitable for Oral Administration
US20120039949A1 (en) 2008-09-04 2012-02-16 Ironwood Pharmaceuticals, Inc. Stable Solid Formulations of GC-C Receptor Agonist Polypeptides Suitable for Oral Administration
AU2009322285B2 (en) 2008-12-03 2016-07-28 Bausch Health Ireland Limited Formulations of guanylate cyclase C agonists and methods of use
US20130012454A1 (en) * 2009-07-06 2013-01-10 Ironwood Pharmaceuticals, Inc. Orally Disintegrating Compositions of Linaclotide
US8748573B2 (en) 2009-08-06 2014-06-10 Ironwood Pharmaceuticals, Inc. Formulations comprising linaclotide
CA2770334A1 (en) 2009-08-12 2011-02-17 Forest Laboratories Holdings Limited Orally disintegrating compositions of linaclotide
HUE034190T2 (en) 2009-11-03 2018-01-29 Ironwood Pharmaceuticals Inc Linaclitaxel for the treatment of chronic constipation

Also Published As

Publication number Publication date
ES2638589T3 (es) 2017-10-23
TR201711271T4 (tr) 2019-02-21
US8933030B2 (en) 2015-01-13
AU2011218009A1 (en) 2012-09-13
CA2790213A1 (en) 2011-08-25
UA108636C2 (xx) 2015-05-25
CN102869677A (zh) 2013-01-09
EA201290799A1 (ru) 2013-03-29
AU2017200588A1 (en) 2017-02-23
CN102869677B (zh) 2015-07-08
US20200283479A1 (en) 2020-09-10
US20140073571A9 (en) 2014-03-13
AU2019202052A1 (en) 2019-04-18
MX340234B (es) 2016-07-01
US20210388026A1 (en) 2021-12-16
US20150094265A1 (en) 2015-04-02
WO2011103311A2 (en) 2011-08-25
AU2011218009B2 (en) 2016-11-03
EP2536742B1 (en) 2017-07-19
US20230340025A1 (en) 2023-10-26
MX2012009597A (es) 2012-09-28
DK2536742T3 (en) 2017-09-04
US20220227812A1 (en) 2022-07-21
WO2011103311A3 (en) 2011-12-29
EP2536742A2 (en) 2012-12-26
US20130190238A1 (en) 2013-07-25
MX386452B (es) 2025-03-18

Similar Documents

Publication Publication Date Title
ZA201203342B (en) Treatments for gastrointestinal disorders
GB2493100B (en) Combination photodynamic devices
PL2652193T3 (pl) Obróbka
IL222481A0 (en) Combination therapy
EP2552323A4 (en) COMBINATION THERAPY
EP2716207A4 (en) ENDOSCOPE DEVICE
EP2716206A4 (en) ENDOSCOPIC DEVICE
EP2609848A4 (en) Borescope
PL2621569T3 (pl) Urządzenie lecznicze
GB201010443D0 (en) Controller
EP2668892A4 (en) Borescope
EP2521569A4 (en) COMBINATION THERAPY WITH VB-201
EP2724658A4 (en) ENDOSCOPIC DEVICE
EP2621498A4 (en) COMBINED TREATMENT OF DERMATOLOGICAL CONDITIONS
EP2664269A4 (en) Borescope
EP2615328A4 (en) REDUCTION DEVICE
GB201001626D0 (en) Controller
PL2510866T3 (pl) Endoskop
GB201013573D0 (en) Treatment
GB201005394D0 (en) Therapy
GB201016864D0 (en) Therapeutic methods
GB201014097D0 (en) Treatment
EP2629766A4 (en) COMBINATION THERAPY
GB201021319D0 (en) Treatment
GB201016304D0 (en) Treatment device